ESMO 2022 Conference Coverage


 

ESMO 2022 on the OS Results From the Phase 3 TROPiCS-02 Study: Sacituzumab Govitecan vs. Treatment of Physician’s Choice in Patients With HR+/HER2- mBC

496 views
September 21, 2022
Comments 0
Login to view comments. Click here to Login